Guidelines should change so that all men over the age of 40 with faults in the BRCA2 gene should be offered regular PSA testing to detect early signs of prostate cancer, experts are urging.
Nov 4, 2019
0
7
A central challenge in diagnosing and treating prostate cancer is distinguishing fast from slow, aggressive from indolent. Consider the experience of Gerald Alexander.
Jun 24, 2015
0
120
A recently published international clinical Phase III trial of a promising drug for treating advanced prostate cancer ended with surprising results: The new therapeutic agent failed to achieve any significant improvement ...
Jul 12, 2016
1
25
Fifteen years ago, Michael Jung was already an eminent scientist when his wife asked him a question that would change his career, and extend the lives of many men with a particularly lethal form of prostate cancer.
Mar 16, 2018
0
363
Getting a close look at the prostate is critical for detecting cancer, but its rather intimate positioning (just in front of the rectum) makes it difficult to image. Now, professor and chair of radiology Sanjiv "Sam" Gambhir, ...
Aug 29, 2019
0
124
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.
Dec 7, 2018
0
385
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...
Dec 13, 2018
0
13
(HealthDay)—A prostate-specific antigen cut point of ≥0.4 ng/mL predicts future disease progression, according to a study published in the June issue of The Journal of Urology.
Jun 20, 2016
1
5
Cambridge scientists have created a comprehensive tool for predicting an individual's risk of developing prostate cancer, which they say could help ensure that those men at greatest risk will receive the appropriate testing ...
Dec 9, 2022
0
390
Research led by the Dana Farber Cancer Institute, Massachusetts, performed a secondary analysis of the Dana-Farber Cancer Institute 05-043 trial. In the paper, "Risk of Short-Term Prostate-Specific Antigen Recurrence and ...
